Bausch Health Companies
BHCBausch Health Companies Inc. is a global specialty pharmaceutical and medical device company focused on gastroenterology, hepatology, neurology, dermatology, and eye health.
Earnings
Next report
Oct 28, 2026 (in a month)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
Bausch Health Companies Inc. is a global specialty pharmaceutical and medical device company focused on gastroenterology, hepatology, neurology, dermatology, and eye health. The company develops, manufactures, and markets a diverse portfolio of branded and generic pharmaceuticals, over-the-counter products, and aesthetic medical devices across approximately 90 countries. A significant portion of its operations is conducted through its majority ownership of Bausch + Lomb, a leading global eye health business.
A leading global player in gastroenterology and eye health with a diversified portfolio of high-barrier-to-entry medical devices and branded pharmaceuticals.
FAQ
- What is Bausch Health Companies's market cap?
- Bausch Health Companies (BHC) has a market capitalization of $2.1B and trades on NYSE.
- What is Bausch Health Companies's revenue and profitability?
- Bausch Health Companies generated $10.5B in trailing twelve-month revenue with a net loss of $1.2B, representing a net margin of -1.9%. Gross margin stands at 71.4%, with free cash flow of $1.0B. The latest reported period is Q1 2026.
- Who are Bausch Health Companies's competitors?
- Bausch Health Companies's key competitors include AbbVie, Bausch + Lomb Corporation, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Bausch Health Companies have?
- Bausch Health Companies's subsidiaries include Bausch + Lomb Corporation, Salix Pharmaceuticals, Solta Medical.
- Where is Bausch Health Companies headquartered?
- Bausch Health Companies is headquartered in Canada and employs approximately 20,270 people. It has been publicly traded since 1994.
